HDAC inihibitors correct frataxin deficiency in a Friedreich ataxia mouse model

142Citations
Citations of this article
109Readers
Mendeley users who have this article in their library.

Abstract

Friedreich ataxia, an autosomal recessive neurodegenerative and cardiac<br />disease, is caused by abnormally low levels of frataxin, an essential<br />mitochondrial protein. All Friedreich ataxia patients carry a GAATTC<br />repeat expansion in the first intron of the frataxin gene, either<br />in the homozygous state or in compound heterozygosity with other<br />loss-of-function mutations. The GAA expansion inhibits frataxin expression<br />through a heterochromatin-mediated repression mechanism. Histone<br />modifications that are characteristic of silenced genes in heterochromatic<br />regions occur at expanded alleles in cells from Friedreich ataxia<br />patients, including increased trimethylation of histone H3 at lysine<br />9 and hypoacetylation of histones H3 and H4.By chromatin immunoprecipitation,<br />we detected the same heterochromatin marks in homozygous mice carrying<br />a (GAA)(230) repeat in the first intron of the mouse frataxin gene<br />(KIKI mice). These animals have decreased frataxin levels and, by<br />microarray analysis, show significant gene expression changes in<br />several tissues. We treated KIKI mice with a novel histone deacetylase<br />inhibitor, compound 106, which substantially increases frataxin mRNA<br />levels in cells from Friedreich ataxia individuals. Treatment increased<br />histone H3 and H4 acetylation in chromatin near the GAA repeat and<br />restored wild-type frataxin levels in the nervous system and heart,<br />as determined by quantitative RT-PCR and semiquantitative western<br />blot analysis. No toxicity was observed. Furthermore, most of the<br />differentially expressed genes in KIKI mice reverted towards wild-type<br />levels.Lack of acute toxicity, normalization of frataxin levels and<br />of the transcription profile changes resulting from frataxin deficiency<br />provide strong support to a possible efficacy of this or related<br />compounds in reverting the pathological process in Friedreich ataxia,<br />a so far incurable neurodegenerative disease.

Cite

CITATION STYLE

APA

Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Coppola, G., … Pandolfo, M. (2008). HDAC inihibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE, 3(4). https://doi.org/10.1371/journal.pone.0001958

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free